EcoDrugPlus

Sodium/potassium-Transporting Atpase Subunit Alpha-2-Like

Ensembl ID : ENSACLG00000003985
Gene Symbol: LOC113011194
3 Cross references
205 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSACLG00000013197
Gene Symbol: LOC113030865
3 Cross references
197 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSACLG00000014611
Gene Symbol: LOC113018315
3 Cross references
191 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-233-Like

Ensembl ID : ENSACLG00000007517
Gene Symbol: LOC113016484
3 Cross references
215 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-233-Like

Ensembl ID : ENSACLG00000024438
Gene Symbol: LOC113015745
3 Cross references
216 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3-Like

Ensembl ID : ENSACLG00000009566
Gene Symbol: LOC113010642
3 Cross references
229 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3-Like

Ensembl ID : ENSACLG00000008585
Gene Symbol: LOC113036702
3 Cross references
230 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSACLG00000005409
Gene Symbol: SLC18A2
3 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6-Like

Ensembl ID : ENSACLG00000019512
Gene Symbol: LOC113030567
3 Cross references
360 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSACLG00000004520
Gene Symbol: SLC29A1
3 Cross references
206 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSACLG00000019177
Gene Symbol: SLC5A1
1 Cross references
242 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSACLG00000011662
Gene Symbol: SLC5A2
1 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).